Bristol-myers Squibb Compnay

Bristol-myers Company

Yosuke Sawada

Toshikazu Oki

Takeo Miyaki

Maki Nishio

Masatoshi Kakushima

Koji Tomita

Tomokazu Ueki

Takashi Tsuno

Satoshi Yamamoto

Masahisa Oka

Hiroaki Ohkuma

Michael R Kozlowski

Koko Sugawara

Kyoichiro Saitoh

Osamu Tenmyo

Masami Hatori

Yutaka Hoshino

Masaru Sugawara

Yasuo Fukagawa

Noriyuki Ohkusa

Derek Hook

The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.

Pradimicins l and fl, and derivatives thereof

Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities.

Compounds produced by a strain of Streptomyces exfoliatus

The present invention relates to an arylsulfatase of microbial origin. The enzyme may be linked to an antibody against a tumor-associated antigen and the resulting conjugate used in conjuction with a sulfated prodrug of a 4'-demethylepipodophyllotoxin glucoside derivative, particularly etoposide in cancer chemotherapy.

Arylsulfatase from streptomyces

The present invention provides BU-4641V of the formula: ##STR1## This invention also provides a biologically pure culture of BU-4641V producing Arthrinium sp. FA1744. Another aspect of the invention provides a process for preparing BU-4641V. Yet further aspect of the present invention provides a method for treating mammalian tumors and bacterial or viral infections.

BU-4641V, an antibacterial, antiviral and antitumor antibiotic

The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.

Process for the preparation of .alpha.-glucosidase inhibitor, pradimicin

Novel compounds derived from cultures of Streptomyces sp. AA2807 are useful as 5-lipoxygenase inhibitors.

Antibiotic 5-lipoxygenase inhibitors

Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Method for treating fungal infections with serine analogs of BU-3608

Actinomadura hibisca microorganism useful for preparing serine analogs

Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.

Process for producing antibiotics BU-3608 D and BU-3608 E

Novel alpha-glucosidase inhibitor, pradimicin Q

Serine analogs of BU-3608 antibiotics

Antibiotics BU-3608D and BU-3608E

Growing community of inventors

Tokyo, Japan

Yosuke Sawada